Syndax Pharmaceuticals’ (SNDX) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...
Q1 Earnings Forecast for SNDX Issued By HC Wainwright
Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Syndax ...
Kalkine Media6d
What’s Driving Market Dynamics Around New Fortress Energy (NASDAQ...
Highlights,New Fortress Energy experiences a range of analyst updates reflecting diverse market perspectives.,The company ...
Kalkine Media6d
What’s Shaping Syndax Pharmaceuticals’ (NASDAQ:SNDX) Growth in Biopharmaceuticals?
Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted ...